Anastrozole vs Exemestane

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Aromatase · full HR+/HER2- Metastatic Breast Cancer pipeline

Anastrozole

Marketed by ANI Pharmaceuticals, Inc. and partners

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07163481 (registry estimate)

Reported efficacy

To assess the difference in event free survival and overall survival (subject to stand-alone or combined/meta-analysis) between postmenopausal women with HR +ve early BC who switched from tamoxifen to anastrozole and those who continued on tamoxifen.: Recurrence-free survival, 2yr tamoxifen then 3yr anastrozole vs 5yr tamoxifen: HR 0.80 (95% CI 0.63-1.01), P=.06 (not statistically significant) (missed)

Result source: NCT00291759

Exemestane

Marketed by Pfizer

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT00002777 · Phase 3 · completed

The study used randomization and an active tamoxifen comparator with an estimated sample size of 342 participants. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2026 · NCT07163481 (registry estimate)

Reported efficacy

Objective response rate: 46% exemestane vs 31% tamoxifen (odds ratio 1.85, 95% CI 1.21-2.82, P=.005). Median progression-free survival (the trial's primary endpoint): 9.9 months exemestane vs 5.8 months tamoxifen; long-term log-rank P=.121 (not statistically significant). (missed)

Result source: NCT00002777

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAnastrozoleExemestane
PFS, median4.8 vs 2.4vs Anastrozolewk 104 · n 103NCT00022672
10 other results
7.3 vs 10vs Capecitabinen 153NCT02028507
14 other results
OS, median20.2 vs 22.5vs Exemestanen 233NCT00253422
4 other results
33.7 vs 32vs Capecitabinen 206NCT02028507
7 other results
ORR45.3%b600 mg · n 188NCT03822468
2 other results
  • 41.5% 400 mg · n 188 · Phase 2 · primary NCT03822468
  • 66.1% vs 61.8% 600 mg · n 112 · Phase 2 · secondary NCT03839823
14.3%bwk 48 · n 49NCT01743560
6 other results
  • 6.1% vs 0% n 49 · Phase 2 · secondary NCT00767520
  • 5.8% vs 6.3% wk 104 · n 52 · Phase 2 · secondary NCT01381874
  • 12.1% vs 6.3% wk 104 · n 66 · Phase 2 · secondary NCT01381874
  • 7% 4 mg + Exemestane · n 43 · Phase 2 · secondary NCT02049957
  • 0% 4 mg + Exemestane · n 35 · Phase 2 · secondary NCT02049957
  • 8.3% n 36 · Phase 2 · secondary NCT00810797
Clinical benefit rate42.7% vs 27.9%vs Anastrozolewk 104 · n 103NCT00022672
3 other results
48.2%bn 199NCT03176238
10 other results
  • 30.6% n 36 · Phase 3 · secondary NCT03176238
  • 44% 4 mg + Exemestane · wk 16 · n 43 · Phase 2 · primary NCT02049957
  • 23% 4 mg + Exemestane · wk 16 · n 35 · Phase 2 · primary NCT02049957
  • 30.6% vs 12.2% wk 24 · n 49 · Phase 2 · secondary NCT00767520
  • 9.6% vs 12.7% wk 104 · n 52 · Phase 2 · secondary NCT01381874
  • 22.7% vs 12.7% wk 104 · n 66 · Phase 2 · secondary NCT01381874
  • 28% 4 mg + Exemestane · wk 24 · n 43 · Phase 2 · secondary NCT02049957
  • 23% 4 mg + Exemestane · wk 24 · n 35 · Phase 2 · secondary NCT02049957
  • 50% n 10 · Phase 2 · secondary NCT02648477
  • 20% n 20 · Phase 2 · secondary NCT02648477

PFS, median

Anastrozole
4.8 vs 2.4vs Anastrozolewk 104 · n 103NCT00022672
10 other results
Exemestane
7.3 vs 10vs Capecitabinen 153NCT02028507
14 other results

OS, median

Anastrozole
20.2 vs 22.5vs Exemestanen 233NCT00253422
4 other results
Exemestane
33.7 vs 32vs Capecitabinen 206NCT02028507
7 other results

ORR

Anastrozole
45.3%b600 mg · n 188NCT03822468
2 other results
  • 41.5% 400 mg · n 188 · Phase 2 · primary NCT03822468
  • 66.1% vs 61.8% 600 mg · n 112 · Phase 2 · secondary NCT03839823
Exemestane
14.3%bwk 48 · n 49NCT01743560
6 other results
  • 6.1% vs 0% n 49 · Phase 2 · secondary NCT00767520
  • 5.8% vs 6.3% wk 104 · n 52 · Phase 2 · secondary NCT01381874
  • 12.1% vs 6.3% wk 104 · n 66 · Phase 2 · secondary NCT01381874
  • 7% 4 mg + Exemestane · n 43 · Phase 2 · secondary NCT02049957
  • 0% 4 mg + Exemestane · n 35 · Phase 2 · secondary NCT02049957
  • 8.3% n 36 · Phase 2 · secondary NCT00810797

Clinical benefit rate

Anastrozole
42.7% vs 27.9%vs Anastrozolewk 104 · n 103NCT00022672
3 other results
Exemestane
48.2%bn 199NCT03176238
10 other results
  • 30.6% n 36 · Phase 3 · secondary NCT03176238
  • 44% 4 mg + Exemestane · wk 16 · n 43 · Phase 2 · primary NCT02049957
  • 23% 4 mg + Exemestane · wk 16 · n 35 · Phase 2 · primary NCT02049957
  • 30.6% vs 12.2% wk 24 · n 49 · Phase 2 · secondary NCT00767520
  • 9.6% vs 12.7% wk 104 · n 52 · Phase 2 · secondary NCT01381874
  • 22.7% vs 12.7% wk 104 · n 66 · Phase 2 · secondary NCT01381874
  • 28% 4 mg + Exemestane · wk 24 · n 43 · Phase 2 · secondary NCT02049957
  • 23% 4 mg + Exemestane · wk 24 · n 35 · Phase 2 · secondary NCT02049957
  • 50% n 10 · Phase 2 · secondary NCT02648477
  • 20% n 20 · Phase 2 · secondary NCT02648477
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety

Coverage. Anastrozole: 14 of 14 rows · Exemestane: 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAnastrozole
Rows use multiple source trials
Exemestane
Rows use multiple source trials
Clinical Benefit
event count · % of participants
28.3% (n=233) vs 23.8% (n=239) Exemestane*a,b
NCT00253422 · Phase 3 · registry result, not featured evidence · combination · converted to % from 66 Participants as posted
76.2% (n=206) vs 82.4% (n=187) Capecitabine*a,b
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 157 Participants as posted
Clinical Benefit
event count · % of participants
No placebo or comparator arm
70.7% (n=188)*600 mgc,d,a,e,b
NCT03822468 · Phase 2 · registry result, not featured evidence · converted to % from 133 Participants as posted
show 1 more dose
75.5% (n=188)*400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence · converted to % from 142 Participants as posted
23.8% (n=239)*d,a,e,b
NCT00253422 · Phase 3 · registry result, not featured evidence · converted to % from 57 Participants as posted
Clinical Benefit
responder rate · % of participants
No placebo or comparator arm
50% (n=10)c,d,f,b
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
20% (n=20)
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
48.2% (n=199)c,d,f,b
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more dose
30.6% (n=36)
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response
time to event · months
8.7 vs 12.8 Exemestane monthsa,b
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
2 other source trials
9.5 vs 10 Anastrozole months @ 104wk
NCT00022672 · Phase 3 · registry result, not featured evidence · combination
12.3 vs 8.2 Anastrozole months
NCT00022672 · Phase 3 · registry result, not featured evidence · combination
9.7 vs 11.2 Capecitabine monthsa,b
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
2 other source trials
6.93 vs 6.47 Exemestane months @ 104wk
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
4.86 vs 6.47 Exemestane months @ 104wk
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
Duration of Response
time to event · months
No placebo or comparator arm
28.8 months600 mgc,d,a,e,b
NCT03822468 · Phase 2 · registry result, not featured evidence
show 1 more dose
26.5 months400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
12.8 monthsd,a,e,b
NCT00253422 · Phase 3 · registry result, not featured evidence
ORR
event count · % of participants
7.3% (n=233) vs 4.2% (n=239) Exemestane*a,b
NCT00253422 · Phase 3 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
22.8% (n=206) vs 29.4% (n=187) Capecitabine*a,b
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 47 Participants as posted
ORR
responder rate · % of participants
No placebo or comparator arm
45.3% (n=188)600 mgc,g,a,e,b
NCT03822468 · Phase 2 · registry result, not featured evidence
show 1 more dose
41.5% (n=188)400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
14.3% (n=49) @ 48wkg,a,e,b
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
3 other source trials
8.3% (n=36)
NCT00810797 · Phase 2 · registry result, not featured evidence
0% (n=35)4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
7% (n=43)4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
ORR
event count · % of participants
No placebo or comparator arm
50% (n=10)*c,d,a,e,b
NCT02648477 · Phase 2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
show 1 more dose
10% (n=20)*
NCT02648477 · Phase 2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
4.2% (n=239)*d,a,e,b
NCT00253422 · Phase 3 · registry result, not featured evidence · converted to % from 10 Participants as posted
2 other source trials
50% (n=10)*
NCT02648477 · Phase 2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
10% (n=20)*
NCT02648477 · Phase 2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
Overall Survival
time to event · months
No placebo or comparator arm
15.6 monthsc,d,a,e,b
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
17.2 months
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
22.5 monthsd,a,e,b
NCT00253422 · Phase 3 · registry result, not featured evidence
4 other source trials
15.6 months
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
17.2 months
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
14 months4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
15.9 months4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
25.1 months600 mgc,g,a,e,b
NCT03822468 · Phase 2 · registry result, not featured evidence
show 1 more dose
26.9 months400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
5.45 months @ 48wk*g,a,e,b
NCT01743560 · Phase 4 · registry result, not featured evidence · combination · converted to months from 23.6 weeks as posted
8 other source trials
3.5 months
NCT00253422 · Phase 3 · registry result, not featured evidence
9.37 months*
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 · converted to months from 40.6 weeks as posted
8.54 months*
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 · converted to months from 37 weeks as posted
5.2 months
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
1.8 months
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
4.3 months
NCT00810797 · Phase 2 · registry result, not featured evidence
3.3 months4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
4.1 months4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
Dropout rate
0%h
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
show 20 more results
84.5%
NCT00022672 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
0%Cohort 1 (Pembrolizumab, Doxorubic
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
0%Cohort 2 (Pembrolizumab, Anti-estr
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
68.8%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
5.6%
NCT00570323 · Phase 2 · registry result, not featured evidence · combination
0%Bevacizumab/Anastrozole
NCT00405938 · Phase 2 · registry result, not featured evidence · combination
0%Bevacizumab/Fulvestrant
NCT00405938 · Phase 2 · registry result, not featured evidence · combination
0%Anastrozole
NCT00259090 · Phase 2 · registry result, not featured evidence
0%Fulvestrant + Anastrozole
NCT00259090 · Phase 2 · registry result, not featured evidence · combination
15.4%
NCT01791985 · Phase 1/2 · registry result, not featured evidence
0%
NCT00217399 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
—160 mg + 1 mg
NCT01597193 · Phase 1 · registry result, not featured evidence · combination
33.3%
NCT01720602 · Phase na · registry result, not featured evidence · combination
0%
NCT01004744 · Phase na · registry result, not featured evidence
29.6%i
NCT01176916 · Phase 4 · registry result, not featured evidence
show 40 more results
—Everolimus + Exemestane
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
82.7%Everolimus and Exemestane
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
0.4%
NCT00253422 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneAsian Everolimus + Exemestane
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
n/a: no completion milestoneNon-Asian Everolimus + Exemestane
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
0%
NCT00083174 · Phase 3 · registry result, not featured evidence
0.1%
NCT00036270 · Phase 3 · registry result, not featured evidence
0%Cohort 1 (Pembrolizumab, Doxorubic
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
0%Cohort 2 (Pembrolizumab, Anti-estr
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02258451 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00810797 · Phase 2 · registry result, not featured evidence
71.7%Abiraterone Acetate + Exemestane +
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
70.8%Abiraterone Acetate + Prednisone
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone5 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone3 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00201864 · Phase 2 · registry result, not featured evidence · combination
13.9%
NCT00767520 · Phase 2 · registry result, not featured evidence · combination
8.7%
NCT00073073 · Phase 2 · registry result, not featured evidence
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
—125mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
91.7%80mg bd 1w/1w + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
—80mg bd 2w/1w + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
100%80mg bd Cont + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
100%40mg Cont + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
—40mg bd Cont + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
100%Part B: AZD4547 + Fulvestrant
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
0%DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%DOSE FINDING PHASE, Arm B, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—h
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
show 20 more results
5.8%
NCT00022672 · Phase 3 · registry result, not featured evidence · combination
12.8%600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
11.2%400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—Cohort 1 (Pembrolizumab, Doxorubic
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
—Cohort 2 (Pembrolizumab, Anti-estr
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
7.1%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—
NCT00570323 · Phase 2 · registry result, not featured evidence · combination
—Bevacizumab/Anastrozole
NCT00405938 · Phase 2 · registry result, not featured evidence · combination
—Bevacizumab/Fulvestrant
NCT00405938 · Phase 2 · registry result, not featured evidence · combination
—Anastrozole
NCT00259090 · Phase 2 · registry result, not featured evidence
—Fulvestrant + Anastrozole
NCT00259090 · Phase 2 · registry result, not featured evidence · combination
13.5%
NCT01791985 · Phase 1/2 · registry result, not featured evidence
—
NCT00217399 · Phase 1/2 · registry result, not featured evidence · combination
14.3%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
—160 mg + 1 mg
NCT01597193 · Phase 1 · registry result, not featured evidence · combination
20%
NCT01720602 · Phase na · registry result, not featured evidence · combination
—
NCT01004744 · Phase na · registry result, not featured evidence
10.8%i
NCT01176916 · Phase 4 · registry result, not featured evidence
show 40 more results
—Everolimus + Exemestane
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
15.4%Everolimus and Exemestane
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
—
NCT00253422 · Phase 3 · registry result, not featured evidence
5.2%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
—Asian Everolimus + Exemestane
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Non-Asian Everolimus + Exemestane
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—
NCT00083174 · Phase 3 · registry result, not featured evidence
—
NCT00036270 · Phase 3 · registry result, not featured evidence
—Cohort 1 (Pembrolizumab, Doxorubic
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
—Cohort 2 (Pembrolizumab, Anti-estr
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
11.3%
NCT02258451 · Phase 2 · registry result, not featured evidence · combination
—
NCT00810797 · Phase 2 · registry result, not featured evidence
—Abiraterone Acetate + Exemestane +
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
—Abiraterone Acetate + Prednisone
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
16.7%5 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
0%4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
17.1%4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
11.6%4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
33.3%3 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
—
NCT00201864 · Phase 2 · registry result, not featured evidence · combination
—
NCT00767520 · Phase 2 · registry result, not featured evidence · combination
—
NCT00073073 · Phase 2 · registry result, not featured evidence
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
—125mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
33.3%80mg bd 1w/1w + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
—80mg bd 2w/1w + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
40%80mg bd Cont + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
20%40mg Cont + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
—40mg bd Cont + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
0%Part B: AZD4547 + Fulvestrant
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
—DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—DOSE FINDING PHASE, Arm B, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
16.9%h
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
show 20 more results
24.3%
NCT00022672 · Phase 3 · registry result, not featured evidence · combination
—600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
19.7%600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
20.2%400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
30%Cohort 1 (Pembrolizumab, Doxorubic
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
10%Cohort 2 (Pembrolizumab, Anti-estr
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
15.2%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
0%
NCT00570323 · Phase 2 · registry result, not featured evidence · combination
26.3%Bevacizumab/Anastrozole
NCT00405938 · Phase 2 · registry result, not featured evidence · combination
29.3%Bevacizumab/Fulvestrant
NCT00405938 · Phase 2 · registry result, not featured evidence · combination
5%Anastrozole
NCT00259090 · Phase 2 · registry result, not featured evidence
7.5%Fulvestrant + Anastrozole
NCT00259090 · Phase 2 · registry result, not featured evidence · combination
19.2%
NCT01791985 · Phase 1/2 · registry result, not featured evidence
34.3%
NCT00217399 · Phase 1/2 · registry result, not featured evidence · combination
57.1%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
5%160 mg + 1 mg
NCT01597193 · Phase 1 · registry result, not featured evidence · combination
13.3%
NCT01720602 · Phase na · registry result, not featured evidence · combination
0%
NCT01004744 · Phase na · registry result, not featured evidence
6.8%i
NCT01176916 · Phase 4 · registry result, not featured evidence
show 40 more results
44.9%Everolimus + Exemestane
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
—Everolimus and Exemestane
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
15.6%
NCT00253422 · Phase 3 · registry result, not featured evidence
22.7%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
—Asian Everolimus + Exemestane
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Non-Asian Everolimus + Exemestane
NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
1.7%
NCT00083174 · Phase 3 · registry result, not featured evidence
17.1%
NCT00036270 · Phase 3 · registry result, not featured evidence
30%Cohort 1 (Pembrolizumab, Doxorubic
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
10%Cohort 2 (Pembrolizumab, Anti-estr
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
43.9%
NCT02258451 · Phase 2 · registry result, not featured evidence · combination
11.1%
NCT00810797 · Phase 2 · registry result, not featured evidence
26.9%Abiraterone Acetate + Exemestane +
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
20.7%Abiraterone Acetate + Prednisone
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
16.7%5 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
33.3%4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
14.3%4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
25.6%4 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
0%3 mg + Exemestane
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
—
NCT00201864 · Phase 2 · registry result, not featured evidence · combination
27.8%
NCT00767520 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00073073 · Phase 2 · registry result, not featured evidence
25%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
100%125mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
83.3%100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
87.5%100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
41.7%80mg bd 1w/1w + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
11.1%80mg bd 2w/1w + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
40%80mg bd Cont + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
—40mg Cont + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
40%40mg bd Cont + Ex 25mg
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
20%Part B: AZD4547 + Fulvestrant
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
0%DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
25%DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
57.1%DOSE FINDING PHASE, Arm B, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
50%Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
33.3%Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
16.7%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
28.6%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
h
lethargy 64.5%
arthralgia 42%
hot flush 37.2%
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
show 17 more results
fatigue 21.4%
vomiting 20.4%
diarrhoea 19.4%
NCT00022672 · Phase 3 · registry result, not featured evidence · combination
600mg
neutropenia 66.5%
leukopenia 27.7%
anaemia 26.1%
NCT03822468 · Phase 2 · registry result, not featured evidence
400mg
neutropenia 53.2%
alanine aminotransferase increased 26.1%
aspartate aminotransferase increased 21.8%
NCT03822468 · Phase 2 · registry result, not featured evidence
fatigue 90%
nausea 90%
white blood cell decreased 90%
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
fatigue 75%
alkaline phosphatase increased 50%
aspartate aminotransferase increased 45%
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
600 mg
neutropenia 65.2%
anaemia 35.7%
leukopenia 25.9%
NCT03839823 · Phase 2 · registry result, not featured evidence
hot flashes 32.4%
arthralgia 20.6%
fatigue 20.6%
NCT00570323 · Phase 2 · registry result, not featured evidence · combination
fatigue 57.9%
hypertension 47.4%
pain - head 44.7%
NCT00405938 · Phase 2 · registry result, not featured evidence · combination
fatigue 73.2%
hypertension 48.8%
proteinuria 43.9%
NCT00405938 · Phase 2 · registry result, not featured evidence · combination
hot flush 20%
headache 7.5%
injection site pain 7.5%
NCT00259090 · Phase 2 · registry result, not featured evidence
headache 10%
pain in extremity 10%
hot flush 7.5%
NCT00259090 · Phase 2 · registry result, not featured evidence · combination
dry mouth 44.2%
nausea 40.4%
alopecia 38.5%
NCT01791985 · Phase 1/2 · registry result, not featured evidence
fatigue 65.7%
diarrhea 62.9%
nausea 60%
NCT00217399 · Phase 1/2 · registry result, not featured evidence · combination
1000 mg
diarrhoea 85.7%
asthenia 71.4%
neutropenia 71.4%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
160 mg + 1 mg
fatigue 60%
decreased appetite 50%
nausea 45%
NCT01597193 · Phase 1 · registry result, not featured evidence · combination
creatinine increase 13.3%
nausea 13.3%
thrombocytopenia 13.3%
NCT01720602 · Phase na · registry result, not featured evidence · combination
diarrhea 40%
fatigue 40%
hot flashes 40%
NCT01004744 · Phase na · registry result, not featured evidence
i
arthralgia 9%
vaginal haemorrhage 5.9%
NCT01176916 · Phase 4 · registry result, not featured evidence
show 35 more results
diarrhoea 44.9%
fatigue 44.9%
cough 36.7%
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
lethargy 56.1%
arthralgia 46.4%
vomiting 38.4%
NCT00253422 · Phase 3 · registry result, not featured evidence
neutrophil count decreased 62.7%
fatigue 55.3%
hypertension 34%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
hot flashes 40.2% (placebo 31.9%)
pain joint 29.7% (placebo 27%)
fatigue 23.4% (placebo 20.7%)
NCT00083174 · Phase 3 · registry result, not featured evidence
hot flush 31.3%
arthralgia 23.8%
fatigue 16.4%
NCT00036270 · Phase 3 · registry result, not featured evidence
fatigue 90%
nausea 90%
white blood cell decreased 90%
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
fatigue 75%
alkaline phosphatase increased 50%
aspartate aminotransferase increased 45%
NCT02648477 · Phase 2 · registry result, not featured evidence · combination
stomatitis 47.5% (placebo 49.6%)
anaemia 39.6% (placebo 28.8%)
decreased appetite 34.5% (placebo 25.2%)
NCT02258451 · Phase 2 · registry result, not featured evidence · combination
hot flashes 66.7%
blood glucose increased 61.1%
aspartate aminotransferase increased 58.3%
NCT00810797 · Phase 2 · registry result, not featured evidence
nausea 21.2%
fatigue 20.2%
vomiting 18.3%
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
fatigue 27.6%
nausea 24.1%
hypokalaemia 21.8%
NCT01381874 · Phase 2 · registry result, not featured evidence · combination
5 mg + Exemestane
nausea 100%
stomatitis 83.3%
fatigue 66.7%
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
4 mg + Exemestane
diarrhoea 66.7%
fatigue 66.7%
nausea 50%
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
4 mg + Exemestane
fatigue 45.7%
hyperglycaemia 45.7%
nausea 42.9%
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
4 mg + Exemestane
nausea 53.5%
fatigue 44.2%
diarrhoea 39.5%
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
3 mg + Exemestane
dyspepsia 100%
abdominal pain 66.7%
arthralgia 66.7%
NCT02049957 · Phase 2 · registry result, not featured evidence · combination
nausea 36.7% (placebo 30.3%)
diarrhoea 31.6% (placebo 9.2%)
asthenia 26.6% (placebo 10.5%)
NCT00767520 · Phase 2 · registry result, not featured evidence · combination
hot flashes 33.3%
arthralgia 31%
fatigue 11.9%
NCT00073073 · Phase 2 · registry result, not featured evidence
cough 25%
dizziness 25%
dyspnoea 25%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
125mg
mucositis oral 100%
neutrophil count decreased 100%
platelet count decreased 100%
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
100mg
mucositis oral 100%
neutrophil count decreased 83.3%
fatigue 50%
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
100mg
mucositis oral 96.9%
neutrophil count decreased 87.5%
fatigue 65.6%
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
80mg bd 1w/1w + Ex 25mg
dry mouth 58.3% (placebo 0%)
alopecia 50% (placebo 0%)
dysgeusia 50% (placebo 0%)
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
80mg bd 2w/1w + Ex 25mg
dysgeusia 66.7% (placebo 0%)
alopecia 55.6% (placebo 0%)
dry mouth 55.6% (placebo 0%)
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
80mg bd Cont + Ex 25mg
alopecia 100% (placebo 0%)
dry mouth 80% (placebo 0%)
diarrhoea 60% (placebo 0%)
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
40mg bd Cont + Ex 25mg
constipation 80% (placebo 0%)
alopecia 60% (placebo 0%)
dry mouth 60% (placebo 0%)
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
dry mouth 80% (placebo 0%)
alopecia 40% (placebo 0%)
asthenia 40% (placebo 0%)
NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination
rash maculo-papular 33.3%
abdominal pain 0%
alanine aminotransferase increased 0%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
rash maculo-papular 50%
abdominal pain 25%
alkaline phosphatase increased 25%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
aspartate aminotransferase increased 28.6%
abdominal pain 14.3%
blood bilirubin increased 14.3%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
rash maculo-papular 33.3%
confusion 16.7%
lymphocyte count decreased 16.7%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
lymphocyte count decreased 33.3%
rash maculo-papular 33.3%
anemia 16.7%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
abdominal pain 0%
alanine aminotransferase increased 0%
alkaline phosphatase increased 0%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
aspartate aminotransferase increased 33.3%
rash maculo-papular 33.3%
alkaline phosphatase increased 16.7%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
lymphocyte count decreased 42.9%
neutrophil count decreased 42.9%
white blood cell decreased 42.9%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bThe assessment timepoint is not available for both results.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dTrial phases differ: Phase 2 versus Phase 3.
  5. eTreatment context has not been resolved for both arms.
  6. fPopulation context differs: eligible sex differs (ALL versus FEMALE).
  7. gTrial phases differ: Phase 2 versus Phase 4.
  8. hPopulation comparability has not been reviewed for these studies.
  9. iPopulation comparability has not been reviewed for 39 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Anastrozole

Duration of Clinical Benefit 11.5 vs 12.2 Exemestane months
time to event · months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
Time to Treatment Failure 18.6 vs 9.1 Combination Chemotherapy months600 mg
time to event · months
NCT03839823 · Phase 2 · registry result, not featured evidence
show 1 more result
3.9 vs 3.4 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
PFS 5.8 vs 2.9 Anastrozole months
time to event · months
End of Study
NCT00022672 · Phase 3 · registry result, not featured evidence · combination
Clinical Benefit 45.6% (n=103) vs 30.8% (n=104) Anastrozole
responder rate · % of participants
End of Study
NCT00022672 · Phase 3 · registry result, not featured evidence · combination
Time to Response 4.9 vs 3.2 Combination Chemotherapy months600 mg
time to event · months
NCT03839823 · Phase 2 · registry result, not featured evidence
show 2 more results
2 vs 2 Anastrozole months @ 104wk
NCT00022672 · Phase 3 · registry result, not featured evidence · combination
2.4 vs 2.1 Anastrozole months
NCT00022672 · Phase 3 · registry result, not featured evidence · combination
OS Rate at 12 52.4% (n=103) vs 45.2% (n=104) Anastrozole @ 104wk
responder rate · % of participants
NCT00022672 · Phase 3 · registry result, not featured evidence · combination
Overall 20.3% (n=74) vs 6.8% (n=73) Anastrozole @ 104wk
responder rate · % of participants
NCT00022672 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
22.3% (n=103) vs 8.7% (n=104) Anastrozole
NCT00022672 · Phase 3 · registry result, not featured evidence · combination
Stable Disease 37.8% (n=74) vs 38.4% (n=73) Anastrozole @ 104wk
event count · % of participants
Stable Disease
NCT00022672 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
47.6% (n=103) vs 40.4% (n=104) Anastrozole
Stable Disease
NCT00022672 · Phase 3 · registry result, not featured evidence · combination
Progressive Disease 40.5% (n=74) vs 49.3% (n=73) Anastrozole @ 104wk
event count · % of participants
Progressive Disease
NCT00022672 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
28.1% (n=103) vs 46.2% (n=104) Anastrozole
Progressive Disease
NCT00022672 · Phase 3 · registry result, not featured evidence · combination
Time to Response 9 months600 mg
time to event · months
No placebo or comparator arm
NCT03822468 · Phase 2 · registry result, not featured evidence
show 1 more result
13.1 months400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
Treatment Failure 11.6% (n=112) vs 21.8% (n=110) Combination Chemotherapy @ 12wk600 mg
responder rate · % of participants
NCT03839823 · Phase 2 · registry result, not featured evidence
FACT-B Total 4.3 vs 4.8 Combination Chemotherapy score @ 6wk600 mg
absolute change · score
NCT03839823 · Phase 2 · registry result, not featured evidence
show 16 more results
5.5 vs 4.4 Combination Chemotherapy score @ 12wk600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
5.9 vs 4.9 Combination Chemotherapy score @ 20wk600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
7.9 vs 6.2 Combination Chemotherapy score @ 28wk600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
7.3 vs 6.5 Combination Chemotherapy score @ 36wk600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
7.2 vs 6.6 Combination Chemotherapy score @ 44wk600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
7.3 vs 4.7 Combination Chemotherapy score @ 56wk600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
7.4 vs 5.1 Combination Chemotherapy score @ 68wk600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
7.1 vs 7 Combination Chemotherapy score @ 80wk600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
9.4 vs 9.6 Combination Chemotherapy score @ 92wk600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
7.9 vs 15.1 Combination Chemotherapy score @ 104wk600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
5.3 vs 15.8 Combination Chemotherapy score @ 116wk600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
2.8 vs 17 Combination Chemotherapy score @ 128wk600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
10.9 vs 20.8 Combination Chemotherapy score @ 140wk600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
3.6 vs 17 Combination Chemotherapy score @ 152wk600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
1.6 vs 33.8 Combination Chemotherapy score @ 164wk600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
16.9 vs 39.7 Combination Chemotherapy score @ 176wk600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence

+ 7 further endpoints in the CSV export.

Exemestane

Disease-free Survival NA months
time to event · months
No placebo or comparator arm
NCT01176916 · Phase 4 · registry result, not featured evidence
Complete 0% (n=49) @ 48wk
responder rate · % of participants
No placebo or comparator arm
Best at WK 48 - Complete Response (CR)
NCT01743560 · Phase 4 · registry result, not featured evidence · combination · converted to % from 0 participants as posted
Partial 14.3% (n=49) @ 48wk
responder rate · % of participants
No placebo or comparator arm
Best at WK 48 - Partial Response (PR)
NCT01743560 · Phase 4 · registry result, not featured evidence · combination · converted to % from 7 participants as posted
Stable Disease 36.7% (n=49) @ 48wk
event count · % of participants
No placebo or comparator arm
Best at WK 48 - Stable Disease (SD)
NCT01743560 · Phase 4 · registry result, not featured evidence · combination · converted to % from 18 participants as posted
Progressive Disease 30.6% (n=49) @ 48wk
event count · % of participants
No placebo or comparator arm
Best at WK 48 - Progressive Disease (PD)
NCT01743560 · Phase 4 · registry result, not featured evidence · combination · converted to % from 15 participants as posted
PFS 67.9% (n=49) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
49.1% (n=49) @ 24wk
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
28.9% (n=49) @ 36wk
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
18.4% (n=49) @ 48wk
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
Overall Survival Event 8 count
event count · count
No placebo or comparator arm
Deaths
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
Overall Survival 93.3% (n=49) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
83.9% (n=49) @ 24wk
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
74.2% (n=49) @ 36wk
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
74.2% (n=49) @ 48wk
NCT01743560 · Phase 4 · registry result, not featured evidence · combination
Duration of Clinical Benefit 12.2 months
time to event · months
No placebo or comparator arm
NCT00253422 · Phase 3 · registry result, not featured evidence
Time to Treatment Failure 3.4 months
time to event · months
No placebo or comparator arm
NCT00253422 · Phase 3 · registry result, not featured evidence
show 2 more results
1.85 months*
NCT01870505 · Phase 1 · registry result, not featured evidence · combination · converted to months from 8 weeks as posted
3.92 months*
NCT01870505 · Phase 1 · registry result, not featured evidence · combination · converted to months from 17 weeks as posted
EORTC QLQ-C30 Global Health Status 3.28 vs 1.97 Capecitabine score
absolute change · score
Global health status / QoL
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Physical Functioning -1.73 vs -2.94 Capecitabine score
absolute change · score
Physical functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination

+ 43 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anastrozole's landscape · Exemestane's landscape